Rebiopsy in patients with untreated hepatitis C: A useful procedure

Página do item simplificado
dc.contributor.authorKhouri, Sandra Tuma [UNIFESP]
dc.contributor.authorPerez, R. M.
dc.contributor.authorOliveira, P. M. de
dc.contributor.authorFigueiredo, V. M.
dc.contributor.authorBarbosa, D. V.
dc.contributor.authorLanzoni, V. P.
dc.contributor.authorSilva, AEB
dc.contributor.authorFerraz, M. L.
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade Federal do Rio de Janeiro (UFRJ)
dc.date.accessioned2016-01-24T12:41:05Z
dc.date.available2016-01-24T12:41:05Z
dc.date.issued2006-04-01
dc.description.abstractBackground: the progression of fibrosis in the early stages of chronic hepatitis C virus is variable, and the ideal interval to perform a new biopsy in untreated patients is still unknown.Aims: We evaluated the histologic progression of patients with untreated hepatitis C virus with two liver biopsies and correlated disease progression with demographic, epidemiologic, biochemical, and histologic variables.Patients and Methods: Untreated hepatitis C virus-infected patients with two liver biopsies at a minimum interval of 1 year were studied. Gender, age, parenteral risk factors, duration of infection, alcohol intake, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase, and histologic findings were analyzed.Results: Fifty-five patients were included. the first biopsy showed low grades of fibrosis and periportal necroinflammatory activity in 93%. A second biopsy was performed after 39 +/- 14 months; 40% of patients showed a progression of fibrosis and/or periportal necroinflammation. Comparison between groups with and without histologic worsening revealed no differences in demographic, epidemiologic, biochemical, or histologic data.Conclusions: Histologic worsening occurred in 40% of untreated patients after 3.2 years. No factor could be established at the first biopsy to predict which patients are at risk of progression. Thus, histologic reassessment between 3 and 5 years seems to be the only approach to document disease progression and establish treatment indication.en
dc.description.affiliationUniversidade Federal de São Paulo, São Paulo, Brazil
dc.description.affiliationUniv Fed Rio de Janeiro, BR-21941 Rio de Janeiro, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent347-352
dc.identifierhttp://dx.doi.org/10.1097/01.mcg.0000210100.36500.3f
dc.identifier.citationJournal of Clinical Gastroenterology. Philadelphia: Lippincott Williams & Wilkins, v. 40, n. 4, p. 347-352, 2006.
dc.identifier.doi10.1097/01.mcg.0000210100.36500.3f
dc.identifier.issn0192-0790
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/28831
dc.identifier.wosWOS:000236992500013
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Gastroenterology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjecthepatitis Cen
dc.subjectliver biopsyen
dc.subjectliver fibrosisen
dc.subjectnatural historyen
dc.titleRebiopsy in patients with untreated hepatitis C: A useful procedureen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral